Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Novel Lipid CBD Formulation
NCT05032807Phase 1Completed
- Sponsor
- King's College London
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cannabidiol in psychotic disorders, epilepsy, anxiety disorders and 1 more (2 arms), sponsored by King's College London. Primary endpoint: Area Under the Curve to Infinity. Started Jul 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
psychotic disordersepilepsyanxiety disorderssubstance use disorder (SUD)
Beyond the preview
Go deeper on NCT05032807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032807.